Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18444663 | Composition for Treating or Preventing Insulin Resistance | February 2024 | September 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18365869 | ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE | August 2023 | March 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18323135 | CAPSID VARIANTS AND METHODS OF USING THE SAME | May 2023 | June 2024 | Allow | 13 | 1 | 2 | Yes | No |
| 18308590 | METHODS OF PREDICTING ANCESTRAL VIRUS SEQUENCES AND USES THEREOF | April 2023 | June 2024 | Allow | 14 | 0 | 1 | No | No |
| 18300124 | COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT | April 2023 | September 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18103343 | ENGINEERED INFLUENZA POLYNUCLEOTIDES, VIRUSES, VACCINES AND METHODS OF MAKING AND USING THE SAME | January 2023 | June 2024 | Allow | 17 | 1 | 1 | No | No |
| 18151803 | CLOSED-ENDED, LINEAR, DUPLEX ADENOASSOCIATED VIRUS DNA, AND USES THEREOF | January 2023 | July 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18079336 | VIRAL VECTOR STABILIZATION | December 2022 | September 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18046267 | FUSION PROTEINS COMPRISING MODIFIED ALPHA VIRUS SURFACE GLYCOPROTEINS AND TUMOR ASSOCIATED ANTIGEN AND METHODS THEREOF | October 2022 | June 2024 | Allow | 20 | 1 | 1 | No | No |
| 17877933 | MICROPOROUS ANNEALED PARTICLE GEL SYSTEM | July 2022 | August 2023 | Allow | 12 | 2 | 1 | Yes | No |
| 17814674 | ENGINEERED CRISPR-CAS SYSTEMS AND METHODS FOR SENSITIVE AND SPECIFIC DIAGNOSTICS | July 2022 | February 2024 | Abandon | 19 | 2 | 1 | No | No |
| 17810729 | HIGH-TRANSDUCTION-EFFICIENCY RAAV VECTORS, COMPOSITIONS, AND METHODS OF USE | July 2022 | April 2024 | Allow | 21 | 1 | 1 | No | No |
| 17806236 | METHODS OF REACTIVATING LATENT HUMAN IMMUNODEFICIENCY VIRUS AND RELATED COMPOSITIONS | June 2022 | September 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17745261 | PROPHYLACTIC PROTECTION AGAINST VIRAL INFECTIONS | May 2022 | April 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17662770 | EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES | May 2022 | June 2024 | Abandon | 25 | 0 | 2 | No | No |
| 17724958 | VIRUS FILTRATION | April 2022 | January 2024 | Allow | 21 | 3 | 1 | Yes | No |
| 17721554 | Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core Antigen | April 2022 | September 2023 | Allow | 17 | 0 | 1 | No | No |
| 17708763 | BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODIES AND METHODS OF USE THEREOF | March 2022 | October 2023 | Allow | 18 | 1 | 1 | No | No |
| 17694115 | MODIFIED VACCINIA VECTORS | March 2022 | May 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17672045 | SYNTHETIC PLASMID DNA VACCINE EXPRESSING A CODON-OPTIMIZED SARS-COV-2 SPIKE PROTEIN AND METHODS FOR ITS USE | February 2022 | July 2023 | Abandon | 16 | 1 | 2 | No | No |
| 17573616 | CHIMERIC MOLECULES AND USES THEREOF | January 2022 | July 2024 | Allow | 30 | 2 | 1 | No | No |
| 17572182 | CORONAVIRUS VACCINE FORMULATIONS | January 2022 | August 2023 | Allow | 20 | 1 | 1 | Yes | No |
| 17569253 | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF | January 2022 | February 2024 | Allow | 26 | 1 | 1 | No | No |
| 17503972 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR TARGETED GENE THERAPY | October 2021 | March 2024 | Allow | 29 | 1 | 1 | No | No |
| 17499555 | METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | October 2021 | April 2022 | Allow | 6 | 1 | 0 | No | No |
| 17499531 | METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | October 2021 | September 2022 | Allow | 12 | 1 | 0 | No | No |
| 17481576 | AAV-BASED CONDITIONAL EXPRESSION SYSTEM | September 2021 | October 2023 | Allow | 24 | 0 | 1 | No | No |
| 17471904 | CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINE | September 2021 | February 2023 | Allow | 17 | 3 | 1 | Yes | No |
| 17466577 | RETROVIRAL VECTOR FOR THE ADMINISTRATION AND EXPRESSION OF REPLICON RNA EXPRESSING HETEROLOGOUS NUCLEIC ACIDS | September 2021 | December 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17466605 | RETROVIRAL VECTOR FOR THE ADMINISTRATION AND EXPRESSION OF REPLICON RNA EXPRESSING HETEROLOGOUS NUCLEIC ACIDS | September 2021 | December 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17398354 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | August 2021 | October 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17378587 | PREFUSION PIV F IMMUNOGENS AND THEIR USE | July 2021 | August 2023 | Allow | 25 | 0 | 1 | No | No |
| 17359324 | AAVRH.10 VARIANTS WITH HOST ANTIBODY ESCAPE CAPABILITIES AND ALTERED TISSUE TARGETING PROPERTIES | June 2021 | February 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17298070 | RECOMBINANT PORCINE PARVOVIRUS ANTIGENIC PROTEIN AND USE THEREOF | May 2021 | June 2024 | Allow | 37 | 0 | 1 | No | No |
| 17319564 | METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | May 2021 | September 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17244106 | MUTANT OF ADENO-ASSOCIATED VIRUS (AAV) CAPSID PROTEIN | April 2021 | January 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17233621 | METHODS AND COMPOSITIONS FOR THE PREPARATION OF AEROSOLS | April 2021 | May 2024 | Allow | 37 | 2 | 1 | No | No |
| 17285786 | FUSION PROTEIN | April 2021 | May 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17229098 | ADENOVECTORS FOR DELIVERY OF THERAPEUTIC GENETIC MATERIAL INTO T CELLS | April 2021 | July 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17222807 | PATHOGEN DIAGNOSTIC TEST | April 2021 | June 2024 | Allow | 39 | 1 | 1 | No | No |
| 17301502 | ONCOLYTIC ADENOVIRUS ENCODING A B7 PROTEIN | April 2021 | August 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17216819 | NON-PSYCHOACTIVE CANNABINOIDS AS ADJUVANTS TO ENHANCE MUCOSAL IMMUNITY | March 2021 | July 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17212327 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | March 2021 | July 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17211632 | Rabies Composition Comprising Pika Adjuvant | March 2021 | May 2024 | Allow | 38 | 2 | 1 | No | No |
| 17209336 | VARIANT ADENO-ASSOCIATED VIRUSES AND METHODS OF USING | March 2021 | November 2023 | Allow | 31 | 2 | 1 | Yes | No |
| 17205990 | CORONAVIRUS VACCINE FORMULATIONS | March 2021 | August 2021 | Allow | 5 | 2 | 1 | No | No |
| 17203978 | METHOD FOR TREATING SUBJECT SUFFERING FROM FLAVIVIRUS INFECTION | March 2021 | April 2023 | Allow | 25 | 2 | 0 | Yes | No |
| 17194834 | PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE | March 2021 | December 2023 | Allow | 33 | 2 | 1 | No | No |
| 17185458 | VACCINES AGAINST CORONAVIRUS AND METHODS OF USE | February 2021 | July 2022 | Allow | 17 | 1 | 1 | No | No |
| 17174587 | RECOMBINANT AAV1, AAV5, AND AAV6 CAPSID MUTANTS AND USES THEREOF | February 2021 | May 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17174244 | IMMUNOASSAY METHODS AND COMPOSITIONS FOR DETECTING INFECTION INVOLVING USE OF TEST ANTIGENS AS CROSS-REACTIVE CONTROL ANTIGENS | February 2021 | October 2023 | Allow | 32 | 2 | 1 | No | No |
| 17170367 | CORONAVIRUS VACCINE FORMULATIONS | February 2021 | September 2022 | Allow | 19 | 1 | 1 | No | No |
| 17130814 | GENOMIC DELETION IN AFRICAN SWINE FEVER VACCINE ALLOWING EFFICIENT GROWTH IN STABLE CELL LINES | December 2020 | June 2023 | Allow | 30 | 1 | 1 | No | No |
| 17251965 | COMPOSITION AND METHOD FOR STABILISING VACCINES IN A SOLID DOSAGE FORMAT | December 2020 | June 2022 | Abandon | 18 | 0 | 1 | No | No |
| 15734263 | RUBELLA VIRUS SPIKE CONSTRUCT | December 2020 | June 2023 | Allow | 31 | 1 | 1 | No | No |
| 17107067 | CONFORMATIONALLY-SPECIFIC VIRAL IMMUNOGENS | November 2020 | June 2023 | Allow | 30 | 1 | 1 | No | No |
| 17104125 | ANTI-INFLAMMATORY POLYPEPTIDES | November 2020 | November 2022 | Allow | 23 | 2 | 2 | Yes | No |
| 16953639 | ANTI-INFLAMMATORY POLYPEPTIDES | November 2020 | November 2022 | Allow | 24 | 2 | 1 | No | No |
| 17057235 | RECOMBINANT MEASLES VIRUS EXPRESSING PROTEINS OF A PLASMODIUM PARASITE AND THEIR APPLICATIONS | November 2020 | August 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17097111 | Methods for Adeno-Associated Viral Vector Production | November 2020 | March 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17096579 | COMPOSITIONS AND METHODS TO TREAT AIDS | November 2020 | February 2023 | Allow | 27 | 1 | 1 | No | No |
| 17082994 | ANTI COVID-19 THERAPIES USING CD40 LIGAND FUSION PROTEIN | October 2020 | September 2022 | Abandon | 23 | 1 | 1 | No | No |
| 17049741 | STEM CELLS COMPRISING SYNTHETIC CHIMERIC VACCINIA VIRUS AND METHODS OF USING THEM | October 2020 | February 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17069680 | COMPOSITIONS AGAINST CAT ALLERGY | October 2020 | October 2022 | Allow | 24 | 1 | 1 | No | No |
| 17067709 | VACCINATION IN NEWBORNS AND INFANTS | October 2020 | July 2024 | Abandon | 45 | 5 | 1 | No | Yes |
| 17067515 | COMPOSITIONS, METHODS AND KITS FOR TREATING COMPLEMENT RELATED DISORDERS | October 2020 | December 2022 | Allow | 27 | 1 | 1 | No | No |
| 17045838 | METHOD FOR PRODUCING GLUCOSE-6-PHOSPHATASE 2 PROTEIN | October 2020 | March 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17064215 | PROPHYLACTIC PROTECTION AGAINST VIRAL INFECTIONS, PARTICULARLY HUMAN PAPILLOMA VIRUS (HPV) | October 2020 | October 2023 | Abandon | 36 | 3 | 1 | No | No |
| 16948930 | DENDRITIC HUMAN UNIVERSAL NON-ANTIGEN EDUCAP VACCINE | October 2020 | September 2022 | Abandon | 23 | 3 | 1 | No | No |
| 17020490 | COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT | September 2020 | January 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 16978657 | AAV CHIMERAS | September 2020 | October 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 17013024 | PERSISTENT TOPICAL ANTIMICROBIAL COMPOSITIONS AND METHODS OF USING THE SAME | September 2020 | February 2022 | Allow | 17 | 2 | 1 | Yes | No |
| 17009929 | MODIFIED ADENOVIRUSES FOR CANCER VACCINES DEVELOPMENT | September 2020 | December 2022 | Allow | 28 | 1 | 1 | No | No |
| 16997001 | CORONAVIRUS VACCINE FORMULATIONS | August 2020 | December 2020 | Allow | 4 | 1 | 1 | No | No |
| 16994882 | Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections | August 2020 | May 2024 | Allow | 45 | 4 | 1 | Yes | No |
| 16989857 | METHODS OF PACKAGING MULTIPLE ADENO-ASSOCIATED VIRUS VECTORS | August 2020 | August 2022 | Allow | 24 | 2 | 1 | Yes | No |
| 16989517 | CORONAVIRUS-TARGETING UNIVERSAL DC CELL VACCINE, AND PREPARATION METHOD AND USE THEREOF | August 2020 | March 2023 | Allow | 31 | 2 | 1 | No | No |
| 16967451 | A PROCESS FOR ENTEROVIRUS PURIFICATION AND INACTIVATION AND VACCINE COMPOSITIONS OBTAINED THEREOF | August 2020 | October 2023 | Allow | 39 | 3 | 1 | No | No |
| 16985736 | IMMUNE COMPOSITION COMPRISING RESPIRATORY SYNCYTIAL VIRUS (RSV) G POLYPEPTIDE | August 2020 | January 2023 | Allow | 30 | 2 | 1 | Yes | No |
| 16964325 | RAPID VERIFICATION OF VIRUS PARTICLE PRODUCTION FOR A PERSONALIZED VACCINE | July 2020 | October 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16964007 | SELF-ANTIGEN SPECIFIC T-CELLS AS VACCINES FOR AUGMENTING ENGRAFTMENT AND STABILITY OF AUTOLOGOUS TRANSFER | July 2020 | February 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 16931600 | Viral Vector Stabilization | July 2020 | September 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16931615 | Viral Vector Stabilization | July 2020 | April 2022 | Allow | 21 | 1 | 0 | No | No |
| 16961857 | Compositions and Methods for Treating Retinal Disorders | July 2020 | January 2023 | Allow | 30 | 1 | 1 | No | No |
| 16959622 | MODIFIED VACCINIA VECTORS | July 2020 | May 2022 | Abandon | 22 | 0 | 1 | No | No |
| 16917131 | RECOMBINANT VERSICAN ISOFORMS AND RELATED COMPOSITIONS AND METHODS | June 2020 | July 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16910845 | VACCINATION IN NEWBORNS AND INFANTS | June 2020 | December 2022 | Allow | 30 | 1 | 1 | No | No |
| 16906849 | METHODS OF PREDICTING ANCESTRAL VIRUS SEQUENCES AND USES THEREOF | June 2020 | June 2022 | Allow | 24 | 1 | 1 | No | No |
| 16955950 | NS2B AS MARKER FOR ZIKA VIRUS INFECTIONS | June 2020 | December 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16954592 | LASSA VACCINE | June 2020 | December 2023 | Allow | 42 | 4 | 1 | No | No |
| 16899763 | STIMULATION OF AN IMMUNE RESPONSE BY ENANTIOMERS OF CATIONIC LIPIDS | June 2020 | August 2023 | Allow | 38 | 3 | 1 | No | No |
| 15931180 | METHODS OF REDOSING GENE THERAPY VECTORS | May 2020 | June 2023 | Allow | 38 | 1 | 1 | No | No |
| 16870816 | NOVEL AAV'S AND USES THEREOF | May 2020 | July 2023 | Allow | 38 | 4 | 1 | No | No |
| 16760269 | ADENOVIRUS AND USES THEREOF | April 2020 | August 2023 | Allow | 40 | 1 | 1 | No | No |
| 16862326 | GENE THERAPY STRATEGY TO RESTORE CARDIAC ELECTRICAL AND STRUCTURAL FUNCTION IN ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY | April 2020 | December 2023 | Allow | 44 | 1 | 1 | No | No |
| 16759868 | RABIES VIRUS VACCINE | April 2020 | January 2024 | Allow | 45 | 5 | 1 | No | No |
| 16758019 | ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, WITH EXPRESSION CONTROL SYSTEM PROVIDING OPTIMAL EXPRESSION LEVEL OF MOUNTED IMMUNOGENIC GENE | April 2020 | October 2023 | Allow | 45 | 2 | 1 | Yes | No |
| 16756377 | SIMIAN ADENOVIRAL VECTORS WITH TWO EXPRESSION CASSETTES | April 2020 | November 2023 | Abandon | 43 | 4 | 1 | Yes | No |
| 16756380 | ADENOVIRAL VECTORS WITH TWO EXPRESSION CASSETTES ENCODING RSV ANTIGENIC PROTEINS OR FRAGMENTS THEREOF | April 2020 | August 2023 | Allow | 40 | 2 | 1 | No | No |
| 16755283 | LIFE-CYCLE-DEFECTIVE ADENOVIRUS HELPER VIRUSES, THEIR PRODUCTION AND USE FOR PRODUCING RAAV | April 2020 | June 2024 | Allow | 50 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SALVOZA, M FRANCO G.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SALVOZA, M FRANCO G works in Art Unit 1648 and has examined 541 patent applications in our dataset. With an allowance rate of 61.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner SALVOZA, M FRANCO G's allowance rate of 61.0% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SALVOZA, M FRANCO G receive 2.17 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SALVOZA, M FRANCO G is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +38.9% benefit to allowance rate for applications examined by SALVOZA, M FRANCO G. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.2% of applications are subsequently allowed. This success rate is in the 27% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 39.7% of cases where such amendments are filed. This entry rate is in the 60% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 93.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 75.8% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.9% of allowed cases (in the 66% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.5% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.